MSOS
AdvisorShares Pure US Cannabis ETF
Price Chart
Latest Quote
$4.04
| Previous Close | $3.97 |
| Open | $3.96 |
| Day High | $4.10 |
| Day Low | $3.98 |
| Volume | 4,050,068 |
Fund Information
| Net Assets | $895.77M |
| Expense Ratio | 0.78% |
| Category | Miscellaneous Sector |
| Fund Family | AdvisorShares |
| Net Asset Value | $3.99 |
| Premium/Discount | 1.25% |
| Exchange | PCX |
đ ETF Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
Technical Indicators
| SMA20 | $4.19 |
| SMA50 | $4.66 |
| SMA200 | $4.46 |
| RSI | 36.13 |
| ATR | 0.2084 |
| Rel Volume | 0.76 |
Performance History
| Week | +1.25% |
| Month | -21.71% |
| Quarter | +0.75% |
| 6 Months | -18.71% |
| YTD | -15.66% |
| Year | -14.95% |
| 3 Years | -39.52% |
| 5 Years | -86.27% |
| 10 Years | -83.58% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $4.04 | 4,050,068 |
| 2026-10-26 | $3.97 | 2,385,800 |
| 2026-10-23 | $3.91 | 4,901,500 |
| 2026-10-22 | $4.08 | 4,384,000 |
| 2026-10-21 | $4.13 | 6,232,700 |
| 2026-10-20 | $3.99 | 5,378,300 |
| 2026-10-19 | $3.81 | 4,336,500 |
| 2026-10-16 | $3.89 | 6,260,900 |
| 2026-10-15 | $4.12 | 3,202,900 |
| 2026-10-14 | $4.08 | 6,878,400 |
| 2026-10-13 | $4.10 | 4,000,100 |
| 2026-10-12 | $4.20 | 2,804,000 |
| 2026-10-09 | $4.34 | 2,803,100 |
| 2026-10-08 | $4.27 | 6,799,400 |
| 2026-10-07 | $4.47 | 2,742,400 |
| 2026-10-06 | $4.45 | 2,750,800 |
| 2026-10-05 | $4.39 | 4,512,700 |
| 2026-10-02 | $4.47 | 8,752,900 |
| 2026-10-01 | $4.60 | 3,104,500 |
| 2026-09-30 | $4.52 | 20,296,800 |
| 2026-09-29 | $5.09 | 5,251,000 |
| 2026-09-28 | $5.16 | 3,191,300 |
About AdvisorShares Pure US Cannabis ETF
The fund is an actively managed ETF that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from the marijuana and hemp business in the United States and in derivatives that have economic characteristics similar to such securities. It will concentrate at least 25% of its investments in the pharmaceuticals, biotechnology & life sciences industry group within the health care sector. The fund is non-diversified.